for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  PharmAsia News
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [13 journals]
  • Emerging Markets Regulatory Tracker: New Indian Rules On API Supplies
    • Abstract: India has issued new rules for allowing local API manufacturers to supply exporters.
      PubDate: Fri, 27 Mar 2015 04:00:00 -040
  • Japan Approvals Include First For Trelagliptin plus Sovaldi, Lenvima
    • Abstract: Japan has approved a batch of new drugs including Gilead's Sovaldi as part of the first all-oral therapy for HCV genotype 2 in the country, Eisai's Lenvima for thyroid cancer, and the world's first once-weekly DPP-4 inhibitor from Takeda.
      PubDate: Fri, 27 Mar 2015 02:55:01 -040
  • Indonesia Penalizes Kalbe Over Suspected Drug Mix-Up Deaths
    • Abstract: Indonesia’s food and drug agency has ordered the country’s largest pharmaceutical company, Kalbe Farma, to suspend production of some of its drugs over a suspected label mix-up that led to the death of two patients.
      PubDate: Thu, 26 Mar 2015 22:10:01 -040
  • Nutraceuticals - At The Cusp Of A Global Surge'
    • Abstract: Nutraceuticals is set to be the next big business segment, for the global health industry as well as Indian drug firms, according to a recent analysis by MP Advisors. But for India to emerge as a meaningful contender, government regulations will need to be streamlined.
      PubDate: Thu, 26 Mar 2015 19:25:02 -040
  • Shionogi Lays Out R&D Goals Ahead of Crestor Challenges
    • Abstract: Japan's Shionogi is looking to bolster its presence in core therapeutic areas, unveiling positive new data for a novel constipation therapy and a raft of anti-infective projects at a recent R&D update.
      PubDate: Thu, 26 Mar 2015 01:10:01 -040
  • With Ranbaxy Under Belt, Sun Eyes Fast Track Global Growth
    • Abstract: Sun and Ranbaxy have finally combined into a single global company, but that could be just the beginning of a series of fresh challenges. Sun said it will look at growing its businesses faster than the industry average in most key markets, and at the same time look to remediate the troubled manufacturing sites of Ranbaxy.
      PubDate: Wed, 25 Mar 2015 23:20:02 -040
  • New Korean Fund Aims For Stem Cell, Gene Therapy Edge
    • Abstract: As some local biosimilar firms such as Celltrion have already got their feet firmly on the ground, the South Korean government is now shifting its strategic focus to support for stem cell and gene therapy ventures to help them advance into a global market where no clear leader has yet emerged.
      PubDate: Wed, 25 Mar 2015 19:30:07 -040
  • Getting Pharma Policy Right The Japanese Way
    • Abstract: If Japan needed any reassurance that it was pursuing the right policy path, at least in the pharma/biotech area, plenty was forthcoming at the BIO Asia 2015 conference in Tokyo.
      PubDate: Wed, 25 Mar 2015 00:50:03 -040
  • Glenmark Takes Merck To Supreme Court Over Januvia Copies
    • Abstract: In a fast-unfolding case, Glenmark has moved the Indian Supreme Court against Merck over copies of Januvia. The Indian drug maker had suffered a setback last week when the Delhi High Court restrained it from further producing and selling copies of the anti-diabetes brand.
      PubDate: Tue, 24 Mar 2015 19:20:00 -040
  • Takeda Takes Chance On ImmunoGen ADC Tech
    • Abstract: ImmunoGen has seen a partial recovery of its share price on news that Takeda has licensed exclusive rights to its antibody-drug conjugated (ADC) technology to develop anticancer therapeutics to two undisclosed targets. In pre-market trading ImmunoGen's shares rose 17% to $8.71 on the news.
      PubDate: Tue, 24 Mar 2015 19:10:03 -040
  • Turkey Regulatory Update: Govt Pricing Policy Criticized, Pharmacies Halt
           Refugee Supplies
    • Abstract: AIFD chairman criticizes government pricing policy and a university launches a new project to develop molecules for the pharmaceutical industry. Meanwhile, pharmacies in Istanbul stop providing prescription drugs to Syrian refugees because of government delays in reimbursement and the SGK adds five generics to the reimbursement list.
      PubDate: Tue, 24 Mar 2015 01:10:05 -040
  • India Lapses Test Relationship But Let’s Listen And Learn: U.S. FDA
    • Abstract: In their latest trip to India, senior U.S. FDA officials mulled several new ideas including a rating system for drug companies, noting that the main aims of the visit were to “listen and learn” and draw up programs that benefit patients in both countries.
      PubDate: Mon, 23 Mar 2015 17:25:04 -040
  • China Faces Doubling Of Diabetes Cost As Disorder Spreads
    • Abstract: Low- and middle-income countries such as China are most affected by the spread of diabetes and face considerable healthcare challenges and economic losses because of it, says a just released academic study.
      PubDate: Mon, 23 Mar 2015 17:25:00 -040
  • India Spares Merck Sec 3(d) Sword, Blocks Glenmark’s Sitagliptin
    • Abstract: In a keenly watched decision, an Indian court has granted an interim injunction to Merck over its anti-diabetes drugs Januvia and Janumet, effectively blocking generic copies launched by Glenmark in 2013.
      PubDate: Mon, 23 Mar 2015 01:35:01 -040
  • Local Expertise, Growing Oncology Market Behind Lilly/Innovent Deal
    • Abstract: The deal just signed between Lilly and Innovent is one of the most wide-ranging so far between a US pharma major and a Chinese biotech, and has the dual attractions of accessing both local capabilities and the growing oncology market in China.
      PubDate: Mon, 23 Mar 2015 01:00:00 -040
  • INTERVIEW: Merck Serono CEO On Growing In A Slowing China
    • Abstract: Despite a slowing Chinese economy and a plethora of layoffs announced by multinational drug makers, Merck KGaA sees growth opportunities via localization and partnering in China. But MNCs have to fully grasp the volatility embedded in the emerging markets, says Merck Serono CEO Belén Garijo.
      PubDate: Sun, 22 Mar 2015 19:20:02 -040
  • Lilly Signs Major Collaboration With Hanmi For RA Drug
    • Abstract: Lilly is building out its autoimmune pipeline through a licensing deal with Hanmi that could be worth $690 million to the Korean firm and is indicative of the growing attractiveness of innovation in the Asian country.
      PubDate: Fri, 20 Mar 2015 02:15:02 -040
  • AZ Alliance Bolsters Daiichi’s US Primary Care Presence
    • Abstract: Daiichi Sankyo is moving to shore up its generic-threatened primary care business in the US through a co-promotion deal with AstraZeneca for a novel constipation drug.
      PubDate: Thu, 19 Mar 2015 23:20:01 -040
  • Identifying The Pitfalls Of Emerging Market M&A
    • Abstract: While major pharma firms continue to see the "pharmerging" markets as attractive given their strong growth prospects, entrants should recognize the sometimes difficult challenges these opportunities can present, particularly for cross-border mergers and acquisitions.
      PubDate: Thu, 19 Mar 2015 19:40:01 -040
  • Samsung Files Remicade Biosimilar In Europe
    • Abstract: Following an approval filing for its Enbrel biosimilar candidate in the EU earlier this year, Samsung is now expanding its European biosimilar ambitions to Remicade.
      PubDate: Thu, 19 Mar 2015 19:35:00 -040
  • U.S., Japan Regenerative Medicine Groups Forge Closer Ties
    • Abstract: A major international regenerative medicine group has taken steps to more closely collaborate with a counterpart in Japan, which is prioritizing the development of the sector as a strategic national priority, to improve co-ordination and information exchange.
      PubDate: Wed, 18 Mar 2015 21:00:01 -040
  • India Embarks On National Health Record Highway
    • Abstract: India has floated a concept note that proposes to set up a National e-Health Authority, a body aiming to oversee a transformation process for a seamless electronic health record highway. Once established, the hope is to avoid duplication and facilitate faster and seamless healthcare delivery across the nation.
      PubDate: Wed, 18 Mar 2015 19:45:01 -040
  • China Drug Approval Backlog Piling Up Fast
    • Abstract: The addition of over 4,000 further products has pushed China’s drug approval backlog towards the 18,600 mark by the end of 2014, with the massive queue causing renewed concerns in the industry.
      PubDate: Wed, 18 Mar 2015 19:40:00 -040
  • Takeda Bigs Up Entyvio As Pillar Of GI Plans
    • Abstract: Amid generic challenges to some of its older mainstay products in the field, Takeda is aiming to convince investors that its commitment to, and prospects in, the gastrointestinal (GI) space remain solid.
      PubDate: Wed, 18 Mar 2015 02:25:02 -040
  • U.S. FDA Officials To Stress Quality, Skilling On India Visit
    • Abstract: On their upcoming visit to India, senior U.S. FDA officials are expected to sign new agreements to work jointly with their local counterparts on issues like skilling and manufacturing processes.
      PubDate: Tue, 17 Mar 2015 19:05:01 -040
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015